Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast CancerShaveta Vinayak, Melinda L. Telli, Andrea E. Wahner-Hendrickson et al.|JAMA Oncology|2019Cited by 446
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) TrialDavid P. Steensma, Hagop M. Kantarjian, Maria R. Baer et al.|Journal of Clinical Oncology|2009Cited by 316
TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.Shaveta Vinayak, Melinda L. Telli, Sara M. Tolaney et al.|Journal of Clinical Oncology|2018Cited by 77